Source comparison
Is MOTS-c Safe Side Effects: Clinical vs Preclinical Comparison
Understanding is MOTS-c safe side effects requires distinguishing between what has been observed in human trials versus what preclinical models predict. The table below compares adverse event profiles, dosing contexts, and duration limits across species. Human
This comparison does not assign a generated winner or score.
- Understanding is MOTS-c safe side effects requires distinguishing between what has been observed in human trials versus what preclinical models predict. The table below compares adverse event profiles, dosing contexts, and duration limits across species.
- Human Clinical Trials (2021–2023)
- 10–15mg subcutaneous, 2–3× weekly
- Injection-site reactions (15–20%), transient nausea (<5%), no serious adverse events
- Maximum 16 weeks documented
- Well-tolerated within research timeframes, but long-term data absent. Cannot extrapolate safety beyond 16 weeks with confidence
- Rodent Preclinical Models
- 0.5–5mg/kg daily (≈3.5–35mg human equivalent)
- No hepatotoxicity, no nephrotoxicity, improved insulin sensitivity, no weight loss in lean animals
- Up to 12 weeks
- No organ toxicity signals, but rodent mitochondrial turnover rates differ from humans. Lifespan effects require primate models
- In Vitro Mitochondrial Studies
- 1–10 µM MOTS-c in isolated mitochondria
- Enhanced oxidative phosphorylation, no cytotoxicity markers, upregulation of SIRT1 and PGC-1α
- Acute exposure only
- Mechanism supports metabolic benefit, but chronic signaling effects on mitochondrial biogenesis feedback loops remain untested
- The clearest takeaway: MOTS-c does not produce high-frequency serious adverse events within the therapeutic window used in current research. What it does produce is a safety evidence gap. No human has been tracked beyond 16 weeks, no study has assessed endogenous MOTS-c suppression after chronic administration, and no trial has enrolled participants with pre-existing mitochondrial disease or mitochondrial DNA mutations. Extrapolating 12-week safety data to year-long protocols requires acknowledging these unknowns explicitly.